Botanix Pharmaceuticals
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
| Company type | Listed Public Company |
|---|---|
| ASX: BOT | |
| Industry | Biotechnology |
| Headquarters | Perth, Western Australia, and Philadelphia, USA |
Area served | Global |
Key people |
|
| Products | BTX 1503 | For the treatment of moderate to severe acne
BTX 1702 | For the treatment of rosacea BTX 1204A | For the treatment of moderate atopic dermatitis BTX 1801 | For use in a variety of antimicrobial applications |
| Website | www |
Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic[1] cannabinoid[2] company, focusing on the compound Cannabidiol.[3] The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex,[4] for direct skin delivery of active pharmaceuticals which is utilised in all of their programs.
Research
[edit]Botanix Pharmaceuticals product pipeline[5] currently[when?] includes four programs for treatment of serious skin diseases:
Dermatology
- BTX 1503, for the treatment of moderate to severe acne
- BTX 1702, for the treatment of rosacea
- BTX 1204A, for the treatment of moderate atopic dermatitis
Antimicrobial
- BTX 1801, for use in a variety of antimicrobial applications
